HighGravityDataCurrent guidance
14 items
Cardinal Health
Guidance from Cardinal Health’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Aug 11, 2026
Data checked
Aug 11, 2026
What changed in the Aug 11, 2026 release
Each item compared with the same item in the previous release (Apr 30, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Global Medical Products and Distribution segment Revenue | for FY2027 | — | “2% to 4% growth” | Filing ↗ |
| New | Other (NPHS, at-Home Solutions, OptiFreight Logistics) Revenue | for FY2027 | — | “11% to 13% growth” | Filing ↗ |
| New | Pharmaceutical and Specialty Solutions segment Revenue | for FY2027 | — | “3% to 5% growth” | Filing ↗ |
| New | Global Medical Products and Distribution segment: Segment profit | for FY2027 | — | “$200 million to $220 million” | Filing ↗ |
| New | Non-GAAP earnings per share | for FY2027 | — | “$12.40 to $12.60” | Filing ↗ |
| New | Other (NPHS, at-Home Solutions, OptiFreight Logistics) segment profit | for FY2027 | — | “15% to 18% growth” | Filing ↗ |
| New | Pharmaceutical and Specialty Solutions segment: Segment profit | for FY2027 | — | “8% to 11% growth” | Filing ↗ |
| New | Capital Expenditures | for FY2027 | — | “~$700 million” | Filing ↗ |
| New | Diluted weighted average shares outstanding | for FY2027 | — | “~233 million” | Filing ↗ |
| New | Interest and other | for FY2027 | — | “$240 million to $290 million” | Filing ↗ |
| New | New distribution center in Indianapolis | for FY2027 | — | “set to open in 2027” | Filing ↗ |
| New | Non-GAAP adjusted free cash flow | for FY2027 | — | “$3.5 billion to $4.0 billion” | Filing ↗ |
| New | Non-GAAP effective tax rate | for FY2027 | — | “19.0% to 20.0%” | Filing ↗ |
Show 1 item not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Targeted leverage range | for the long term | “2.75 - 3.25X” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Next year and medium term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Global Medical Products and Distribution segment Revenue | “2% to 4% growth” | for FY2027 | GAAP-tied | Aug 11, 2026 | 1 | Filing ↗ |
| Other (NPHS, at-Home Solutions, OptiFreight Logistics) Revenue | “11% to 13% growth” | for FY2027 | GAAP-tied | Aug 11, 2026 | 1 | Filing ↗ |
| Pharmaceutical and Specialty Solutions segment Revenue | “3% to 5% growth” | for FY2027 | GAAP-tied | Aug 11, 2026 | 1 | Filing ↗ |
| Global Medical Products and Distribution segment: Segment profit | “$200 million to $220 million” | for FY2027 | Company-defined | Aug 11, 2026 | 1 | Filing ↗ |
| Non-GAAP earnings per share | “$12.40 to $12.60” | for FY2027 | Company-defined | Aug 11, 2026 | 1 | Filing ↗ |
| Other (NPHS, at-Home Solutions, OptiFreight Logistics) segment profit | “15% to 18% growth” | for FY2027 | Company-defined | Aug 11, 2026 | 1 | Filing ↗ |
| Pharmaceutical and Specialty Solutions segment: Segment profit | “8% to 11% growth” | for FY2027 | Company-defined | Aug 11, 2026 | 1 | Filing ↗ |
| Capital Expenditures | “~$700 million” | for FY2027 | Company-defined | Aug 11, 2026 | 1 | Filing ↗ |
| Diluted weighted average shares outstanding | “~233 million” | for FY2027 | GAAP-tied | Aug 11, 2026 | 1 | Filing ↗ |
| Interest and other | “$240 million to $290 million” | for FY2027 | Company-defined | Aug 11, 2026 | 1 | Filing ↗ |
| New distribution center in Indianapolis | “set to open in 2027” | for FY2027 | Company-defined | Aug 11, 2026 | 1 | Filing ↗ |
| Non-GAAP adjusted free cash flow | “$3.5 billion to $4.0 billion” | for FY2027 | Company-defined | Aug 11, 2026 | 1 | Filing ↗ |
| Non-GAAP effective tax rate | “19.0% to 20.0%” | for FY2027 | Company-defined | Aug 11, 2026 | 1 | Filing ↗ |
| Share repurchases | “~$1 billion” | for FY2027 | Declared action | Aug 11, 2026 | 1 | Filing ↗ |
Long term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Targeted leverage range | “2.75 - 3.25X” | for the long term | Company-defined | Feb 5, 2026 | 2 | Filing ↗ |
No period stated
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Regular quarterly dividend | “$0.5158 per share” | — | Declared action | Aug 11, 2026 | 1 | Filing ↗ |
How one item moved
Diluted weighted average shares outstanding, for FY2026 — every statement across the year, each linked to its filing.
How your Healthcare payers & distributors sector group guides
12 companies in Healthcare payers & distributors. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| UnitedHealth Group | Oct 13, 2026 | 5 changes |
| Cardinal Health | Aug 11, 2026 | 13 changes |
| Cencora | Aug 5, 2026 | 11 changes |
| CVS Health | Aug 5, 2026 | 5 changes |
| McKesson | Aug 5, 2026 | 1 change |
| Labcorp | Jul 30, 2026 | 2 changes |
| The Cigna Group | Jul 30, 2026 | 3 changes |
| Humana | Jul 29, 2026 | 4 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2027 | FY2026 | FY2025 | Long-term | No period |
|---|---|---|---|---|---|
| Global Medical Products and Distribution segment Revenue | 1 statement | 1 statement | — | — | — |
| Other (NPHS, at-Home Solutions, OptiFreight Logistics) Revenue | 1 statement | 1 statement | — | — | — |
| Pharmaceutical and Specialty Solutions segment Revenue | 1 statement | — | — | — | — |
| For non-GAAP diluted EPS attributable to Cardinal Health, Inc. | — | 3 statements | — | — | — |
| Global Medical Products and Distribution segment profit | — | 2 statements | 2 statements | — | — |
The full record for Cardinal Health and its Healthcare payers & distributors peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Aug 11, 2026 | FY2026 Q4 | 0000721371-26-000037 | 16 | Open filing ↗ |
| Apr 30, 2026 | FY2026 Q3 | 0000721371-26-000017 | 9 | Open filing ↗ |
| Feb 5, 2026 | FY2026 Q2 | 0000721371-26-000004 | 8 | Open filing ↗ |
| Oct 30, 2025 | FY2026 Q1 | 0000721371-25-000128 | 9 | Open filing ↗ |
| Aug 12, 2025 | FY2025 Q4 | 0000721371-25-000075 | 13 | Open filing ↗ |
| May 1, 2025 | FY2025 Q3 | 0000721371-25-000036 | 9 | Open filing ↗ |
| Jan 30, 2025 | FY2025 Q2 | 0000721371-25-000009 | 6 | Open filing ↗ |
| Nov 1, 2024 | FY2025 Q1 | 0000721371-24-000119 | 4 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error